Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long-chain triglyceride (LCT)
- Target
- LCT
- Molecular classification
- Lipid, Fat, Triacylglycerol (triglyceride), Other
01
Overview
Long-chain triglyceride is an ester compound formed from glycerol and three long-chain fatty acids—typically with 16, 18, or 20 carbons each. LCTs are a major form of energy storage in humans and other animals, and they constitute the bulk of edible fats and oils derived from plants and animals. They are colorless and generally solid or oily at room temperature, depending on exact structure. In metabolism, LCTs are broken down by lipases into glycerol and free fatty acids, entering pathways for energy production or biosynthesis. LCTs do not act as receptors, enzymes, or transporters, but their levels and metabolism are important for health, particularly in relation to lipid disorders, cardiovascular risk, obesity, and metabolic syndrome. If you require structured target data for drug discovery or pharmacology purposes, "Long-chain triglyceride" is not a canonical therapeutic target. It is a substrate/metabolite type and should not be annotated as a druggable target.
- Other names
- Long-chain triacylglycerolLCTLong-chain fatLong-chain TAG
02
Mechanism of action
Not applicable. LCT is a substrate/metabolite, not a target. Enzymes such as lipases hydrolyze long-chain triglyceride for digestion/metabolism.
03
Biological functions
Energy storageInsulationComponent of cell membranes (minor role)Substrate for β-oxidation and lipid metabolism
04
Disease associations
Cardiovascular disease (elevated levels associated with increased risk)ObesityMetabolic syndromeOther (as dietary fat, relevant to malabsorption syndromes and certain inherited metabolic diseases)
05
Safety considerations
Elevated long-chain triglyceride levels are associated with increased risk of cardiovascular disease, pancreatitis, and can reflect poor metabolic healthDietary sources high in LCT may contribute to obesity and metabolic syndrome if consumed in excess
06
Interacting drugs
No drugs directly target long-chain triglyceride as a molecule. However, drugs may influence metabolic pathways that regulate triglyceride synthesis, breakdown, or plasma levels (e.g., fibrates, statins, omega-3 fatty acids influence triglyceride levels but do not bind or inhibit LCT directly).
07
Biomarkers
Plasma triglyceride level (used in cardiovascular risk assessment)
Beyond the preview
Go deeper on Long-chain triglyceride (LCT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long-chain triglyceride (LCT).